WVE-003
Early / Mid-stage
completed
completed
CT.gov grounded
An allele-selective Huntington's program that matters for the field's longer-run precision ambitions.
Program overview
- Mechanism
- allele-selective HTT silencing
- Modality
- oligonucleotide
- Phase
- Early / Mid-stage
- Status
- completed
- Recruitment
- completed
- Confidence
- medium
- Watch priority
- 3
- Last verified
- 20 Apr 2026
Sponsor and trial identifiers
- Sponsor
- Wave Life Sciences
- Trial IDs
- NCT05032196
ClinicalTrials.gov exact matches: NCT05032196
Regions and recruitment
Australia
Canada
Denmark
France
Germany
Italy
Netherlands
Poland
Spain
United Kingdom
Indication tags
Huntington's disease
allele-selective
Milestones and catalysts
- Last milestone
- One of the more conceptually interesting allele-selective Huntington's programs to have reached the clinic.
- Next expected catalyst
- How much of the allele-selective approach survives into future development strategy.
Related pages
Disease hub
Huntington's disease hub
Disease-specific views with programs, mechanisms, and related context.
Related programs
Each card explains why it is here so you can read the overlap at a glance.
Early / Mid-stage
active
active, not recruiting
One of the most strategically important Huntington's programs because it represents a direct gene-therapy path rather than a small-molecule or ASO variant.
- Mechanism
- HTT-lowering gene therapy
- Modality
- AAV gene therapy
- Next catalyst
- Longer-run safety and functional read-throughs from treated cohorts.
- Last verified
- 20 Apr 2026
Mid-stage
active
active, not recruiting
Huntingtin-lowering antisense program with unusually high field significance.
- Mechanism
- huntingtin-lowering antisense
- Modality
- ASO
- Next catalyst
- Updated data from the redesigned development path.
- Last verified
- 20 Apr 2026
Early / Mid-stage
active
recruiting
A repeat-targeting oligonucleotide program that broadens the Huntington's pipeline beyond the biggest legacy names.
- Mechanism
- RNA modulation of expanded repeats
- Modality
- antisense oligonucleotide
- Next catalyst
- Safety, pharmacokinetic, and early pharmacodynamic read-throughs.
- Last verified
- 20 Apr 2026
Late-stage
completed
completed
A major Huntington's program that deserves inclusion as part of the real clinical history of the field, not just the surviving winners.
- Mechanism
- sigma-1 receptor agonism
- Modality
- small molecule
- Next catalyst
- Mainly interpretation and strategic follow-through rather than a clean new expansion path.
- Last verified
- 20 Apr 2026